Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
To assess the dangers of malignancies, infections and autoimmune ailments in patients with rheumatoid arthritis (RA) handled with abatacept compared with other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic (cs)DMARDs, in a US-wide observational RA cohort METHODS: Data have been reviewed from patients (≥ 18 years) with RA who have been registered with …